ВестникНОМУС
.
Сборникматериаловнаучной
сессии
-2013
590
2.
Бессмельцев
С
.
С
.,
Абдулкадыров
K.
М
.
Диагностическое
значение
эхографии
селезенки
,
абдоминальных
лимфоузлов
и
сосудов
при
хроническомлимфо
-
имиелолейкозе
//
Тер
.
арх
.- 1990.N7.-
С
. 63-67.
3.
Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic
myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia
chromosome.// Science. 1990.-Vol.247. - PP.824-830.
4.
Deininger M. W., Vieira S., Mendiola R. et al. BCR-ABL tyrosine kinase
activity regulates the expression of multiple genes implicated in the pathogenesis
of chronicmyeloid leukemia // CancerRes. 2000. -Vol. 60. - P. 2049—2055.
5.
Druker B.J., Guilhot F., O'Brien S.G. et al. // Five-year follow-up of patients
receiving imatinib for chronicmyeloid leukemia // N. Engl. J. Med., 2006, V.355,
№
23, P.2408-2417.
6.
Fialkow P.J., Jacobson M.B., Papayannopoulou T. Chronic myelocytic
leukemia: clonal origin in a stem cell common to granulocyte, erythrocyte, platelet
andmonocyte/macrophage. //Am JMed. 1997. -Vol.3. - PP. 125-130.
7.
KantarjianH., TalpazM., O'BrienS. High-dose imatinibmesylate therapy in
newly diagnosed Philadelphia chromosome-positive chronic phase chronic
myeloid leukemia. //Blood.- 2004.-Vol.l03.-PP.2873-2878.
8.
Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a
chronicmyelogenous leukemia-like syndrome inmicewith v-abl andBCR/ABL.//
Proc. Natl. Acad. Sci.U. S. A.- 1990.-Vol.87.-PP.6649-6653.
9.
LugoT.G., Pendergast A.M.,MullerA.J.,WitteO.N. Tyrosin kinase activity
and transformation potency of bcr-abl oncogene products.// Science.- 1990.-
Vol.247.-PP. 1079-1082.
10.
Nowell P.C., Hungerford D. A. A minute chromosome in human chronic
granulocytic leukemia // Science. 1960. - Vol. 132. - P. 1497—1501.
